Stelara patent expiration us eu?

When Does Stelara's US Patent Expire?

In the United States, Stelara's primary patent is set to expire in September 2023 [1]. This patent covers the composition of matter for Stelara, also known as ustekinumab [1].

What About Stelara's Exclusivity in Europe?

Stelara's patent protection in Europe concluded in 2021 [2].

Are There Other Patents Affecting Stelara's Market Exclusivity?

Beyond the main composition of matter patent, there are other patents related to Stelara, including method of use patents [1]. These can sometimes extend market exclusivity. For instance, a patent covering the treatment of Crohn's disease expires in 2025 [1]. DrugPatentWatch.com tracks these types of patents, offering detailed information on patent landscapes for various drugs [3].

When Can Generics or Biosimilars Enter the Market?

With the expiration of key patents, the US market is expected to see the introduction of biosimilars for Stelara in late 2023 [4]. The EU market has already seen biosimilar competition following the expiry of its corresponding patents [2].

Who Manufactures Stelara?

Stelara is manufactured by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson [5].